Eloralintide news and clinical trials

Eli Lilly and Company registered a Phase 3 trial to investigate the safety and efficacy of eloralintide and tirzepatide coformulation compared with tirzepatide, eloralintide, and placebo in 2115 adults with obesity.

Eli Lilly and Company registered a Phase 3 study to evaluate the efficacy and safety of eloralintide and tirzepatide coformulation compared to tirzepatide in 1000 adults with obesity or overweight and type 2 diabetes.

A review published in Diabetes Therapy examines the efficacy of amylin-based agonists, reporting that eloralintide achieved weight loss of up to 20.1% in a phase 2 study. The authors note the drug is associated with fatigue, headache, and appetite loss.

A review in Cardiology in Review evaluates early studies of eloralintide, noting potential cardiometabolic benefits including reductions in body weight, blood pressure, and pulse rate. The authors emphasize that no dedicated cardiovascular outcomes trial has been conducted.

Eli Lilly and Company completed a phase 2 study investigating the safety and efficacy of LY3841136 and tirzepatide, alone or in combination, for weight management in 367 adults with obesity or overweight and type 2 diabetes.

Eli Lilly and Company is recruiting 34 female participants for a Phase 1 study to evaluate how eloralintide affects the pharmacokinetics of oral contraceptives in individuals with obesity or overweight.

Eli Lilly and Company registered a phase 1 study to assess the safety, tolerability, and pharmacokinetics of macupatide monotherapy and its combination with eloralintide in 60 Japanese participants with obesity or overweight.

A review article in Pharmacological Research summarizes the biology and development of amylin-based therapeutics like eloralintide and cagrilintide. The authors explore how receptor pharmacology influences weight-loss efficacy and gastrointestinal tolerability.

Eli Lilly and Company is recruiting 56 participants for a phase 1 study to measure how significantly eloralintide slows stomach emptying in individuals with obesity or overweight.

A review in Diabetes, Obesity & Metabolism examines the role of amylin-based therapies, including eloralintide and cagrilintide, as an alternative to GLP-1 treatments. The authors highlight that these newer long-acting analogues demonstrate clinically meaningful weight loss.

Eli Lilly and Company registered a phase 1 study in 58 healthy participants to evaluate the safety, tolerability, and pharmacokinetics of two different eloralintide solutions.

Eli Lilly and Company completed a phase 2 study of eloralintide (LY3841136) in 263 participants with obesity or overweight. The study investigated the efficacy and safety of the drug compared to a placebo over 64 weeks.

Eli Lilly and Company is recruiting 115 participants for a phase 1 study to compare the effects of eloralintide against a placebo on insulin sensitivity, metabolic health, and body weight in adults with obesity or overweight.

Researchers developed an open-source integration engine within the TermX platform to improve data exchange between healthcare systems. This project aims to simplify semantic interoperability through modular mediators and visual interfaces for non-technical users.

New review in Endocrinology, diabetes & metabolism: Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis.

Eli Lilly and Company is recruiting 400 participants for a Phase 2b study examining the body weight-lowering efficacy and safety of macupatide and eloralintide, used alone or in combination, in adults with obesity or overweight.

A review of obesity pharmacotherapy indicates a shift toward multi-receptor agonists and personalized treatment strategies. Emerging therapies such as retatrutide and oral amylin analogs show promise in achieving significant weight loss and improving metabolic outcomes.

A review describes second-generation amylin analogs like eloralintide, petrelintide, and amycretin as promising agents for obesity and type 2 diabetes management. These long-acting peptides show strong efficacy and potential therapeutic benefits for fatty liver and kidney complications.

Eli Lilly and Company is conducting a phase 1 study to assess the pharmacokinetics of eloralintide in 28 participants with varying levels of renal function, including severe renal impairment and end stage renal disease.

Eli Lilly and Company registered a phase 1 study to assess the pharmacokinetics and tolerability of eloralintide in 36 participants with varying levels of hepatic impairment compared to those with normal liver function.

Eli Lilly and Company is recruiting 900 participants for a phase 3 study to evaluate the safety and efficacy of weekly eloralintide compared to placebo in adults with persistent obesity or overweight who are already taking a weekly incretin.

Eli Lilly and Company is recruiting 800 participants for a Phase 3 study investigating the efficacy and safety of once-weekly eloralintide in adults with moderate to severe obstructive sleep apnea and obesity or overweight.

Eli Lilly and Company is recruiting 900 participants for a Phase 3 master protocol study to investigate the efficacy and safety of once-weekly eloralintide in adults with obesity or overweight and osteoarthritis knee pain.

A Phase 1 trial of the amylin receptor agonist eloralintide in 100 participants showed weight reductions ranging from 2.6% to 11.3% after 12 weeks of once-weekly subcutaneous dosing. The treatment was generally well tolerated with infrequent gastrointestinal side effects.

Eli Lilly and Company completed a phase 1 study of 188 participants to evaluate the safety, tolerability, and relative bioavailability of eloralintide and eloralintide combined with tirzepatide.

Eli Lilly and Company is recruiting 1980 participants for a phase 3 study comparing the safety and efficacy of weekly eloralintide against a placebo in adults with obesity or overweight who do not have type 2 diabetes.

Eli Lilly and Company is recruiting 1035 participants for a Phase 3 study evaluating the efficacy and safety of once-weekly eloralintide compared to placebo for body weight reduction in adults with obesity or overweight and type 2 diabetes.

Eli Lilly and Company completed a phase 1 study with 128 Japanese participants to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of eloralintide monotherapy and combination therapy with tirzepatide.

New randomized trial in Lancet (London, England): Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial.